BRM has been notified by the (NIDDK) to be in the competitive range for two contracts entitled “Preclinical Study of Efficacy in Animal Models of Type 1 Diabetes” and “Preclinical Study of Efficacy I Animal Models of Diabetic Complications”.
NIDDK has developed the T1D Rapid Access to Intervention Development (RAID) program. Under the aegis of this program, resources will be provided to investigators to bridge the gap between discovery and clinical testing. A major component of this program is in vivo efficacy testing.
To support in vivo testing, an animal testing center that can provide reliable, standardized, cost-effective studies is required. Under our proposal, BRM would serve as a primary resource for performing preclinical studies in mice and rats to test new therapeutics for the prevention and/or treatment of type 1 diabetes and it’s complications.